drugset / Trial / NCT00288431

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

NCT00288431

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to determine the safety, tolerability and maximum tolerated dose of Oral AP23573 in combination with Doxorubicin

Timeline

Start
2006-02
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 60 mg/m2 Intravenous
Subject ridaforolimus Small molecule 10 mg Oral
Subject ridaforolimus Small molecule 30 mg Oral

Indications